Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press33010.17650/1726-9776-2010-6-4-32-35DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиTHE AUTHOR’S EXPERIENCE IN USING BEVACIZUMAB PLUS INTERFERON ALFA-2A IN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMAСОБСТВЕННЫЙ ОПЫТ ПРИМЕНЕНИЯ КОМБИНАЦИИ БЕВАЦИЗУМАБ + ИНТЕРФЕРОН ƒ-2А У БОЛЬНЫХ ДИССЕМИНИРОВАННЫМ ПОЧЕЧНО-КЛЕТОЧНЫМ РАКОМPopovA. M.ПоповА. М.
Russian Federation
apopov@mrrc.obninsk.ruKaryakinO. B.КарякинО. Б.
Russian Federation
apopov@mrrc.obninsk.ruGorbanN. A.ГорбаньН. А.
Russian Federation
apopov@mrrc.obninsk.ruMedical Radiology Research Center, Russian Academy of Medical Sciences, ObninskГУ МРНЦ РАМН, Обнинск301220106432350608201406082014https://oncourology.abvpress.ru/oncur/article/view/330

Target therapy is a main approach to treating metastatic renal cell carcinoma. Bevacizumab plus interferon alfa-2A is now standard first-line options for patients with previously untreated, good or intermediate prognosis (using the Memorial Sloan-Kettering Cancer Center criteria). We have presented our experience in using bevacisumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma. Median progression-free survival and overall survival were 10 months and 22 months, respectively.

Таргетная терапия является основным методом лечения больных диссеминированным раком почки. В настоящее время комбинацию бевацизумаба с интерфероном (ИФН) α-2А в качестве 1-й линии считают стандартом лечения больных метастатическим почечно-клеточным раком с благоприятным и промежуточным прогнозом (по критериям MSKCC). Мы представили собственный опыт применения бевацизумаба с ИФН α-2А у больных метастатическим раком почки. Медиана времени до прогрессирования и медиана общей выживаемости составили 10 и 22 мес соответственно.

renal cell carcinomatarget therapybevacisumabvascular endothelial growth factor inhibitorпочечно-клеточный рактаргетная терапиябевацизумабинтерферонингибитор VEGF1. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies againstadvanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96.Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies againstadvanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96.2. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–11.Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–11.3. Escudier B., Bellmunt J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall surviva. J Clin Oncol 2010;28:2144–50.Escudier B., Bellmunt J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall surviva. J Clin Oncol 2010;28:2144–50.4. Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Ann of Oncol 2008;19(8):1470–6.Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Ann of Oncol 2008;19(8):1470–6.5. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9.Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9.6. Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;22;358 (9286):966–70.Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;22;358 (9286):966–70.7. Dham A., Dudek A. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO 2007;abstr 5106.Dham A., Dudek A. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO 2007;abstr 5106.8. Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. ASCO 2007;abstr 5038.Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. ASCO 2007;abstr 5038.9. Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.